LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Stock List・Incyte Corp
Search

Incyte Corp

Closed

SectorHealthcare

97.03 -0.48

Buy

Price update 22 May 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

95.97

Max

98.03

Key metrics

By Trading Economics

Income

4.1M

303M

Sales

-234M

1.3B

P/E

Sector Avg

13.445

49.701

EPS

1.81

Profit margin

23.834

Employees

2,844

EBITDA

-47M

367M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+11.17% upside

Dividends

By Dow Jones

Next Earnings

28 Jul 2026

Market Stats

By TradingEconomics

Market Cap

-31M

19B

Previous open

97.51

Previous close

97.03

News Sentiment

By Acuity

25%

75%

47 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

59.52 / 62.66 Support & Resistance

Incyte Corp Chart

Past performance is not a reliable indicator of future results.

Related News

22 May 2026, 16:33 UTC

Earnings
Major Market Movers

Webull Shares Slide on 1Q Loss, Soaring Costs

DJ

Read

22 May 2026, 21:10 UTC

Earnings

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

DJ

Read

22 May 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

22 May 2026, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

DJ

Read

22 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

DJ

Read

22 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

22 May 2026, 19:47 UTC

Earnings

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

DJ

Read

22 May 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

DJ

Read

22 May 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

DJ

Read

22 May 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

22 May 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

DJ

Read

22 May 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

DJ

Read

22 May 2026, 18:35 UTC

Acquisitions, Mergers, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

DJ

Read

22 May 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

DJ

Read

22 May 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

DJ

Read

22 May 2026, 17:54 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

DJ

Read

22 May 2026, 17:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

22 May 2026, 17:54 UTC

Market Talk

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

DJ

Read

22 May 2026, 17:03 UTC

Market Talk

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

DJ

Read

22 May 2026, 16:54 UTC

Market Talk

Crypto Spot Volumes Fall 14% in April -- Market Talk

DJ

Read

22 May 2026, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

DJ

Read

22 May 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

DJ

Read

22 May 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

DJ

Read

22 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

22 May 2026, 16:16 UTC

Market Talk

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

DJ

Read

22 May 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Read

22 May 2026, 15:55 UTC

Market Talk

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

DJ

Read

22 May 2026, 15:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

22 May 2026, 15:42 UTC

Market Talk

Oil Continues as Leading Indicator for All Markets -- Market Talk

DJ

Read

22 May 2026, 15:35 UTC

Market Talk

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

DJ

Read

Peer Comparison

Price change

Incyte Corp Forecast

Price Target

By TipRanks

11.17% upside

12 Months Forecast

Average 108.29 USD  11.17%

High 135 USD

Low 75 USD

Based on 19 Wall Street analysts offering 12 month price targets forIncyte Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

8

Buy

10

Hold

1

Sell

Based on 19 analysts giving stock ratings to Incyte Corp - Dist in the past 3 months.

Technical Score

By Trading Central

59.52 / 62.66Support & Resistance

Short Term

Bullish Evidence

Bullish events outweigh bearish events.

Intermediate Term

Bearish Evidence

All events are bearish.

Long Term

Bearish Evidence

All events are bearish.

Sentiment

By Acuity

47 / 345 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation

Other stocks from the sector

LLY

Eli Lilly and Co.

1,066.82

↑ +2.48%

JNJ

Johnson and Johnson

234.57

↑ +1.33%

ABBV

AbbVie Inc

216.12

↑ +0.45%

UNH

UnitedHealth Group Inc

388.17

↑ +1.5%

AZN

AstraZeneca PLC

187.25

↓-1.32%
help-icon Live chat